2023 World Conference on Lung Cancer (Posters)-EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report

EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report - PDF(Slides)

Back to course

Pdf Summary

This case report describes the treatment of a patient with metastatic non-small cell lung cancer (NSCLC), who had an epidermal growth factor receptor (EGFR) mutation (T790M positive) and MET amplification. Osimertinib, a standard treatment for NSCLC with EGFR T790M mutation, was combined with capmatinib as a late-line treatment. The patient, a 70-year-old woman, initially presented with chronic cough and multiple bone pain. Further testing revealed EGFR exon 21 L858R mutation and negative results for other mutations. She received erlotinib as frontline treatment and achieved a partial response. However, 21 months later, disease progression was observed and osimertinib was administered as second-line treatment. The patient had stable disease until she developed progressive dyspnea. Pulmonary adenocarcinoma with TTF-1 positive was confirmed, along with EGFR exon21 L858R, exon20 T790M, TP53 mutations, and MET amplification. Osimertinib was then combined with capmatinib as third-line treatment. The patient initially had stable disease but decided to stop further treatment due to performance status decline and pursue best supportive care. The efficacy of the combination therapy was different from previous reports, indicating a marginal effect in this subgroup. This case highlights the potential benefit of combining osimertinib and capmatinib in patients with NSCLC who have both EGFR T790M mutation and MET amplification.

Asset Subtitle

Kijjakom Thanasombunsukh

Meta Tag

Speaker Kijjakom Thanasombunsukh

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

metastatic non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutation

T790M positive

MET amplification

osimertinib

capmatinib

late-line treatment

pulmonary adenocarcinoma